All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date||2004-004309-69||A randomized phase II study of gemcitabine/cisplatin with or without Cetuximab to evaluate the efficacy in patients with locally advanced or metastatic EGFR-positive pancreatic cancer. SpaCe TRIAL.||bad-data|
|Ongoing||2007-000354-31||A randomized trial investigating the role of FOLFOX-4 regimen duration (3 versus 6 months) and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer||not-yet-due|
|Completed, but no date||2007-001781-32||A randomized phase II study of gemcitabine/cisplatin with or without sorafenib to evaluate the efficacy and safety in patients with locally advanced or metastatic pancreatic cancer. MAPS trial||bad-data|
|Ongoing||2007-006254-26||Open-label randomized, parallel group, phase III, multicenter trial comparing two different sequences of therapy (irinotecan/cetuximab followed by fluorouracil/leucovorin with oxaliplatin ...||not-yet-due|
|Completed, but no date, and reported results||2008-004637-16||Folfiri as Second-Line chemotherapy for Advanced Pancreatic cancer: a GISCAD Phase II study FOLFIRI come trattamento di seconda linea nel carcinoma del pancreas avanzato. Studio di Fase II della ...||bad-data|
|Completed, but no date, and reported results Terminated||2011-005537-39||A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric...||bad-data|
|Ongoing||2012-005048-46||First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH FOLFIRI e bevacizumab nel trattamento di prima linea in pazienti con c...||not-yet-due|
|Ongoing||2013-002973-23||A Phase II randomized trial comparing a combination of Abraxane and Gemcitabine versus Gemcitabine alone as first line treatment in locally advanced unresectable pancreatic cancer. Studio clinico d...||not-yet-due|
|Ongoing||2017-002219-33||seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status seconD-line folfiri/aflIbercept in proSpe...||not-yet-due|
|Ongoing||2020-003080-26||A randomized phase II trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC). Studio randomizza...||not-yet-due|